Literature DB >> 8368986

The effects of Benadryl and Hismanal on psychomotor performance and perceived performance.

V J Rice1, H L Snyder.   

Abstract

Classic antihistamines (H1 antagonists) have sedative effects and can impair psychomotor performance. It is claimed that Hismanal (astemizole) does not possess central nervous system side effects. A three-factor, repeated measures, double-blind design was used to compare the effects of single oral doses of (1) Benadryl (diphenhydramine)-50 mg, (2) Hismanal-10 mg, and (3) placebo on a battery of 11 cognitive information-processing tasks and performance ratings in 28 healthy men. Performance decrements were seen at 1 h post-Benadryl ingestion on Following Directions (p < 0.05), at 1.5 h on Unstable Tracking (p < 0.05), and at 3 h on serial addition/subtraction (p < 0.05). No decrements in performance were found post-Hismanal. Subjects perceived their performance as poorer following Benadryl ingestion versus placebo and Hismanal for 3 h postingestion (p < 0.05). Results demonstrate performance effects post-Benadryl ingestion for 1 h longer than previously reported. Tasks which demonstrated sensitivity to antihistamines were those which required an element of sustained attention and those which required a visual-motor response.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8368986

Source DB:  PubMed          Journal:  Aviat Space Environ Med        ISSN: 0095-6562


  2 in total

1.  Driving ability after acute and sub-chronic administration of levocetirizine and diphenhydramine: a randomized, double-blind, placebo-controlled trial.

Authors:  Joris C Verster; A Marit de Weert; Saskia I R Bijtjes; Mounir Aarab; Armand W A A van Oosterwijck; Erik J E Eijken; Marinus N Verbaten; Edmund R Volkerts
Journal:  Psychopharmacology (Berl)       Date:  2003-04-30       Impact factor: 4.530

2.  Functional neuroimaging of cognition impaired by a classical antihistamine, d-chlorpheniramine.

Authors:  N Okamura; K Yanai; M Higuchi; J Sakai; R Iwata; T Ido; H Sasaki; T Watanabe; M Itoh
Journal:  Br J Pharmacol       Date:  2000-01       Impact factor: 8.739

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.